Individual differences and evidence-based psychopharmacology
Rh Belmaker1, Yuly Bersudsky, Galila Agam
1Ben Gurion University of the Negev, Beersheva, Israel. belmaker@bgu.ac.il
BMC Medicine
|September 29, 2012
Summary
Individual responses to psychopharmacology vary, even in controlled studies. Patient history remains key for effective personalized medicine, moving beyond average treatment effects.
Area of Science:
- Pharmacology
- Genetics
- Personalized Medicine
Background:
- Randomized controlled trials (RCTs) provide mean treatment effects, but individual variability limits their clinical utility.
- Significant individual differences in treatment response are observed even within genetically uniform populations, such as inbred mouse strains.
- Current approaches often overlook unique patient factors, leading to suboptimal therapeutic outcomes.
Purpose of the Study:
- To highlight the limitations of relying solely on mean data from clinical trials.
- To emphasize the importance of individual variability in pharmacologic treatment response.
- To advocate for the integration of individual patient history in personalized medicine for psychopharmacology.
Main Methods:
- Review of existing literature on randomized controlled trials and individual treatment responses.
- Analysis of data from genetically uniform inbred mouse strains to demonstrate inherent variability.
- Conceptual framework development for personalized medicine in psychopharmacology.
Main Results:
- Mean data from RCTs do not fully capture the spectrum of individual responses to pharmacologic treatments.
- Genetic uniformity does not eliminate significant inter-individual differences in treatment outcomes.
- Individual patient history emerges as a critical factor for tailoring psychopharmacologic interventions.
Conclusions:
- Personalized medicine in psychopharmacology necessitates a shift from population-level data to individual patient profiles.
- Stratification in large studies can help, but individual history is paramount for precise treatment selection.
- Integrating comprehensive patient history is the most effective strategy for optimizing psychopharmacologic treatments.
Related Concept Videos
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Human Genetics
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...